Enter multiple symbols separated by commas

Stocks Gilead Sciences Inc


  • Yelp and Twitter are big market movers Wednesday, 29 Jul 2015 | 4:25 PM ET

    NEW YORK— Stocks that moved substantially or traded heavily Wednesday on the New York Stock Exchange and the Nasdaq Stock Market:. Yelp Inc., down $8.45 to $25.06. Twitter Inc., down $5.30 to $31.24.

  • July 29- Express Scripts Holding Co, the largest pharmacy benefit manager in the United States, on Wednesday said the cost of potent, newly approved cholesterol drugs could "wreak financial havoc" among its clients. Express Scripts, which administers drug benefits for employers and health plans and also runs large mail-order pharmacies, has been challenging...

  • *Fed statement expected at 2 p.m. ET. *Yelp falls sharply after revenue misses expectations. The statement is expected at 2 p.m. ET.

  • US STOCKS-U.S. futures higher ahead of Fed statement Wednesday, 29 Jul 2015 | 7:28 AM ET

    July 29- U.S. stock index futures rose on Wednesday on hopes that Beijing could stem the rout in its markets and ahead of a statement from the U.S. *In a recent congressional testimony, Fed Chair Janet Yellen neither ruled out a September interest rate hike nor guided the market toward thinking it was a done deal. The statement is expected at 2 p.m. ET.

  • NEW YORK— U.S. stocks rose on Wednesday after Federal Reserve policymakers voted to keep interest rates unchanged and gave no indication that a rate rise was imminent. "Yeah, the economy is improving, but they are not really saying that the economy is taking off here," said Tom di Galoma, head of rates trading at ED&F Man Capital. There are several reasons why the Fed...

  • July 28- Gilead Sciences Inc said on Tuesday sales of its hepatitis C drugs hit a record of nearly $5 billion, surpassing Wall Street estimates as strong demand offset pricing pressures and restrictions on patient use from U.S. health insurers. Excluding items, Gilead earned $3.15 a share in the second quarter, beating the $2.71 average forecast by Wall Street...

  • Gilead posts huge beat on earnings and revenue Tuesday, 28 Jul 2015 | 5:28 PM ET
    A scientist at Gilead Sciences analyzes patient antibody levels at the Gilead laboratory in Foster City, California.

    Gilead blew past top and bottom line expectations on the strength of strong sales for its hepatitis C treatments.

  • Harvoni and a second hepatitis C drug, Sovaldi, together posted sales about $500 million above expectations and HIV medicine sales were higher-than-expected across all products, noted Edward Jones analyst Ashtyn Evans. Gilead, based in Foster City, California, said Tuesday that its net income was $4.49 billion, or $2.92 per share. Revenue soared to $8.24...

  • July 28- Gilead Sciences Inc said on Tuesday its quarterly net profit rose 32 percent, driven by sales of hepatitis C drugs that beat Wall Street estimates. Looking ahead, Gilead raised its outlook for full-year 2015 product sales by $1 billion to between $29 billion and $30 billion. Excluding items, Gilead earned $3.15 a share in the second quarter, exceeding the...

  • *Focus on corporate results eclipses China worry. *Twitter and Gilead up after the bell; Yelp drops. "The S&P has had five down days in a row and a lot of people are starting to nibble," said Michael Matousek, head trader at U.S. Global Investors Inc in San Antonio, which manages about $1 billion.

  • Gilead beats Street 2Q forecasts Tuesday, 28 Jul 2015 | 4:15 PM ET

    FOSTER CITY, Calif.— FOSTER CITY, Calif.— Gilead Sciences Inc. on Tuesday reported second-quarter earnings of $4.49 billion. The average estimate of 10 analysts surveyed by Zacks Investment Research was for earnings of $2.64 per share. Six analysts surveyed by Zacks expected $7.36 billion.

  • Top trades to go: Earnings edition Tuesday, 28 Jul 2015 | 1:43 PM ET

    The "Halftime Report" traders give their trades on earnings for the second half.

  • Minefield for market with Fed, earnings, commodities Monday, 27 Jul 2015 | 8:08 AM ET
    An oil trader works on the floor of the New York Mercantile Exchange.

    The Fed meets next week, but a commodities meltdown and earnings season are adding to concerns about global growth and may steal some of its thunder.

  • Cramer game plan—My Fed-pectations in week ahead Friday, 24 Jul 2015 | 6:13 PM ET
    Federal Reserve Board Chair Janet Yellen testifies before a House Financial Services committee hearing on Capitol Hill in Washington, July 15, 2015.

    Jim Cramer lays out his game plan next week. It will all about the Fed, Fed, Fed with a side of China.

  • Battle coming for blockbuster cholesterol drugs Friday, 24 Jul 2015 | 3:59 PM ET
    A Sanofi lab worker packages vaccines.

    One large pharmacy benefit manager warns that costs from new PCSK9 drugs could reach as high as $150 billion annually.

  • TRENTON, N.J.— An experimental drug for one of the hardest-to-treat types of hepatitis C has been approved by the Food and Drug Administration, adding to the surge of new options— all much more effective but extremely costly— for patients with the liver-destroying virus. Daklinza, developed by New York- based Bristol-Myers Squibb Co., is the first drug approved to...

  • July 24- The U.S. Food and Drug Administration on Friday approved two treatments for less common forms of hepatitis C virus infections. The regulator cleared AbbVie Inc's Technivie, which targets HCV genotype 4 infections, and Bristol-Myers Squibb Co's Daklinza, used to treat HCV genotype 3 infections. Technivie, includes the same cocktail of drugs that...

  • *AbbVie CEO sees 2015 Humira growth in mid-teens. July 24 (Reuters)- AbbVie Inc reported quarterly revenue that missed analysts' estimates for the first time in six quarters, sparking concerns over slowing sales growth for its flagship arthritis drug, Humira. AbbVie reported total Humira sales of $3.54 billion for the quarter ended June 30, a 7.6 percent fall from a...

  • Health care takes earnings hot hand into week ahead Friday, 24 Jul 2015 | 10:23 AM ET
    Pfizer headquarters in New York.

    Health-care stocks are batting 12 for 12 in beating earnings estimates. Will the streak last?

  • July 24- AbbVie Inc on Friday reported quarterly revenue that missed analysts' estimates for the first time in six quarters, sending its shares down 3 percent in premarket trading. Deutsche Bank analyst Robyn Karnauskas attributed the revenue miss to smaller-than-expected sales of AbbVie's hepatitis C treatment, Viekira Pak, in the United States.